Quarterly Activities/Appendix 4C Cash Flow Report
Filed with ASX · · 12 pages · English
• Phase 2 data for ATH434 in Multiple System Atrophy (MSA) strengthened by additional analyses and multiple international scientific presentations during the quarter. • Regulatory planning activities advancing toward a pivotal Phase 3 program, including preparation for FDA End-Of-Phase-2 meeting in mid-2026. • Ongoing partnering and strategic discussions with pharmaceutical companies and corporate
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Alterity Therapeutics Issues Shareholder Letter Highlighting 2025 Progress and Key Objectives for 2026
- Alterity Board Changes
- Alterity Therapeutics to Present at the Bell Potter Healthcare Virtual Conference
- Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSA at the 36th International Symposium on the Autonomic Nervous System
- Alterity Therapeutics Presents Promising Impact of ATH434 on Orthostatic Hypotension and Disease Progression in MSAat the 36th International Symposium on the Autonomic Nervous System
Later from Alterity Therapeutics
- Alterity Therapeutics: Appendix 4C – Q2 FY26 Quarterly Cash Flow Report & Corporate Update
- Half Yearly Report and Accounts
- Alterity Therapeutics Recognizes Multiple System Atrophy (MSA) Awareness Month in March and the Urgent Need for Disease-Modifying Treatments
- Alterity Therapeutics Appoints Daniel O. Claassen, M.D., M.S., as Chief Medical Advisor
- Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics